Density of striatal D2 receptors in untreated first-episode psychosis: An I 123-IBZM SPECT study

European Neuropsychopharmacology

Volumn 21, Issue 12, 2011, Pages 861-866

  Corripio, Iluminada ^a,b   Escartí, María J ^b,c   Portella, Maria J ^a,b   Pérez, Víctor ^a,b   Grasa, Eva ^a,b   Sauras, Rosa B ^a,b   Alonso, Anna ^a,b   Safont, Gemma ^d   Camacho, M Valle ^a   Dueñas, Rosa ^e   Arranz, Belén ^b,e   San, Luis ^b,f   Catafau, Ana M ^g   Carrió, Ignasi ^a   Álvarez, Enric ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c Clinic Hospital of Valencia   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e PARC SANITARI SANT JOAN DE DÉU   (Spain)

^f HOSPITAL SANT JOAN DE DÉU   (Spain)

^g Barcelona Imaging Group   (Spain)

Author keywords

First psychotic episode; I 123 IBZM SPECT; Outcome; Schizophrenia; Striatal dopaminergic receptors

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; IODINE 123; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RECEPTOR BINDING; RECEPTOR DENSITY; SCHIZOPHRENIA; SENSITIZATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; BIOLOGICAL MARKERS; CORPUS STRIATUM; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82855175292     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.03.004     Document Type: Article

References (32)

1. Addington J., van Mastrigt S., Addington D. Patterns of premorbid functioning in first-episode psychosis: initial presentation. Schizophr. Res. 2003, 62:23-30.
2. Álvarez E., García-Ribera C., Torrens M., Udina C., Guillamat R., Casas M. Premorbid adjustament scale as a prognostic predictor for schizophrenia. Br. J. Psychiatry 1987, 150:411.
3. Bach M.E., Simpson E.H., Kahn L., Marshall J.J., Kandel E.R., Kellendonk C. Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proc. Natl Acad. Sci. USA 2008, 14:16027-16032.
4. Bigliani V., Pilowsky L.S. In vivo neuropharmacology of schizophrenia. Br. J. Psychiatry Suppl. 1999, 38:23-33.
5. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., Kemether E., Oakes T.R., Mukherjee J. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006, 85:232-244.
6. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8:470-484.
7. Corripio I., Pérez V., Catafau A.M., Mena E., Carrió I., Alvarez E. Striatal D2 receptor binding as a prognosis and outcome in untreated first-psychosis. Neuroimage 2006, 29:662-666.
8. Grace A.A. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J. Neural Transm. Gen. Sect. 1993, 91:111-134.
9. Graff-Guerrero A., Mizrahi R., Agid O., Marcon H., Barsoum P., Rusjan P., Wilson A.A., Zipursky R., Kapur S. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009, 34:1078-1086.
10. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15:2550-2559.
11. Kay S.R., Fiszbein A., Opler L.A. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
12. Kegeles L.S., Martinez D., Kochan L.D., Hwang D.R., Huang Y., Mawlawi O., Suckow R.F., Van Heertum R.L., Laruelle M. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002, 43:19-29.
13. Kellendonk C., Simpsom E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-617.
14. Kestler L.P., Walker E., Vega E.M. Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav. Pharmacol. 2001, 12:355-371.
15. Knapp M., Mangalore R., Simon J. The global costs of schizophrenia. Schizophr. Bull. 2004, 30:279-293.
16. Kolachana B.S., Saunders R.C., Weinberger D.R. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience 1985, 69:859-868.
17. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q. J. Nucl. Med. 1998, 42:211-221.
18. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20:423-451.
19. McGlashan T.H. A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr. Bull. 1988, 14:515.
20. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
21. Pérez V., Catafau A., Corripio I., Martin J.C., Álvarez E. Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:767-770.
22. Ramírez N., Arranz B., Salavert J., Alvarez E., Corripio I., Dueñas R.M., Pérez V., San L. Predictors of schizophrenia in patients with a first episode of psychosis. Schizophr. Res. 2009, 115:58-66.
23. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
24. Suhara T., Okubo Y., Yasuno F., Sudo Y., Inoue M., Ichimiya T., Nakashima Y., Nakayama K., Tanada S., Suzuki K., Halldin C., Farde L. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 2002, 59:25-30.
25. Schmitt G.J., Meisenzahl E.M., Frodl T., La Fougère C., Hahn K., Möller H.J., Dresel S. Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. Psychiatry Res. 2009, 173:183-189.
26. Talvik M., Nordstrom A.L., Okubo Y., Olsson H., Borg J., Halldin C., Farde L. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 2006, 148:165-173.
27. Tatsch K., Asenbaum S., Bartenstein P., Catafau A., Halldin C., Pilowsky L.S., Pupi A. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine D(2) receptor ligands. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:23-29.
28. Van Laere K., Varrone A., Booij J., Vander Borght T., Nobili F., Kapucu O.L., Walker Z., Någren K., Tatsch K., Darcourt J. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:434-442.
29. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
30. Wilkinson L.S., Dias R., Thomas K.L., Augood S.J., Everitt B.J., Robbins T.W., Roberts A.C. Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response of D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 1997, 80:717-730.
31. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J.K., Malat J., Williams J.A., O'Tuama L.A., Snyder S.H., Kuhar M.J., Gjedde A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 19:1558-1563.
32. Zakzanis K.K., Hansen K.T. Dopamine D2 densities and the schizophrenic brain. Schizophr. Res. 1998, 32:201-206.